200
Participants
Start Date
June 30, 2025
Primary Completion Date
November 1, 2028
Study Completion Date
May 1, 2029
Debamestrocel - MSC-NTF (NurOwn)
MSC-NTF cells suspended in excipient Dulbecco Modified Eagle Medium (DMEM).
Placebo
Dulbecco Modified Eagle Medium (DMEM).
Temple University Of The Commonwealth System of Higher Education, Philadelphia
Mayo Clinic, Jacksonville
Nova Southeastern University, Davie
University of South Florida, Tampa
Mayo Clinic, Rochester
Northwestern Medicine, Chicago
University of Colorado Anschutz Medical Campus School of Medicine, Aurora
Barrow Neurological Institute, Phoenix
University of Southern California, Los Angeles
University of California San Diego Medical Center, La Jolla
California Pacific Medical Center, San Francisco
University of California, San Francisco, San Francisco
Providence ALS Center, Portland
Sean M. Healey & AMG Center For ALS At Massachusetts General Hospital, Boston
University of Massachusetts Medical School, Worcester
Lead Sponsor
Brainstorm-Cell Therapeutics
INDUSTRY